Navigation Links
Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver
Date:10/13/2010

ts was at least 3 years.  There was no evidence of tumor development in either group.

Dr. Millis commented, "This is the first time that a long term survival benefit has been demonstrated in subjects who recovered following treatment with ELAD. It is highly encouraging to note that those subjects that survive in the short term are able to go on to extended survival without any apparent increase in mortality or morbidity compared with subjects administered standard of care."

Dr. Duan, who served as a principal investigator for the study, commented, "China has about 95 million HBV carriers and chronic hepatitis B patients, and 38 million hepatitis C patients. It is estimated that 0.1%-0.5% of these patients will experience severe hepatitis due to acute hepatocellular necrosis or hypofunction, which results in hepatic insufficiency and hepatic failure. Mortality from this condition still remains around 50%-70% even with comprehensive internal medicine treatment, leading to as many as 400,000 deaths per year in China from acute liver failure. When approved for commercial sale in China, ELAD will be the first bioartificial liver support system proven to improve survival in this population."

In order to confirm these findings from China, VTI is conducting the SILVER (Stabilization In LiVER Failure) trial in the United States, Europe and Saudi Arabia which has achieved 50% of its targeted enrollment. Should this study yield positive findings, these results, along with data from other studies, will form the basis of regulatory filings for future marketing authorization.  

About ELAD and the SILVER Trial

The SILVER protocol enrolls subjects with chronic liver disease who have been hospitalized as a result of an event, such as an infection or an episode of bleeding, which has caused deterioration of their liver function (acute-on-chronic liver failure, ACLF). The trial is designed to explore whet
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
3. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
4. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
5. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
6. Comfort Medical Supply, LLC Ranks No. 461 on the 2010 Inc. 500 with Three-Year Sales Growth of 649%
7. Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600%
8. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
11. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, ... secondary analysis of its double-blind, randomized, controlled Phase ... a gene therapy product designed to deliver the ... analysis identified a more robust response to CERE-120 ... to treatment relative to those diagnosed 10 years ...
(Date:5/21/2013)... Calif. , May 21, 2013 /PRNewswire/ ... ), a specialty pharmaceutical company focused on ... for the treatment of acute and breakthrough ... in a placebo-controlled Phase 3 study of ... analgesia) System (NanoTab System), the primary efficacy ...
Breaking Medicine Technology:Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... RA Signs and Symptoms Compared to Placebo, ... (Nasdaq: TRBN ) today announced preliminary ... double-blind, placebo-controlled, multicenter,clinical trial of its TRU-015 ... indicated that Trubion,s TRU-015 product candidate, at,well-tolerated ...
... Calif., Sept. 10 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... antibodies for the treatment of cancer and,hepatitis C ... submitted a,clinical protocol with the Drug Controller General ... safety and efficacy trial of bavituximab in combination,with ...
Cached Medicine Technology:Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 2Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 3Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 4Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis 5Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 2Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 3Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer 4
(Date:5/21/2013)... Dr. James C. Wittig, Chief of Orthopedic ... Division of the John Theurer Cancer Center at Hackensack ... one of the top 13 Orthopedic Oncologists in the ... is one of approximately 125 surgeons in America who ... surveying thought leaders in the field of Oncology. Dr. ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... information on the site for patients taking the blood ... drug may be at more risk of death when ... , DrugRisks was created to improve the safety of ... warnings, recalls, studies and legal news. Visitors can see ...
(Date:5/20/2013)... The India Network Foundation, a ... insurance, announces a new pre-existing condition coverage plan: ... the years, India Network members have requested a ... maximums, and duration. The Platinum Comprehensive Plan is ... the valuable coverage and benefits of a PPO ...
(Date:5/20/2013)... Southfield, Michigan (PRWEB) May 21, 2013 This ... National Dog Bite Prevention Week (May 19th-May 25th) is an ... dog bite attacks and by encouraging dog owners to properly ... a dog. , Michigan dog bite lawyers at ... animal attacks in cases throughout Michigan. The personal injury law ...
(Date:5/20/2013)... May 20, 2013 When people ... not always to become a celebrity. New Jersey ... 2013 ABC News report (“Chris Christie Says Lap ... clear that the surgery was not done so ... gain celebrity status as a former lap band ...
Breaking Medicine News(10 mins):Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 2Health News:James C. Wittig, MD, Selected as one of America's Top 13 Orthopaedic Oncologists 3Health News:DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 2Health News:Indian Network announces Platinum Comprehensive Visitor Health Insurance Plan with Pre-existing Condition Choices for Visitors on Short Term Trip to the United States 3Health News:Buckfire & Buckfire, P.C. Dog Bite Lawyers in Michigan Discuss National Dog Bite Prevention Week 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3
... Feb. 4 The Carol Milgard Breast Center was awarded ... (FDA) for adhering to the most rigorous quality and safety standards ... "All Items in Compliance" rating from the FDA is exceptional because ... high quality standard.   , John Peixotto , M.D., a ...
... American Society for Radiation Oncology (ASTRO) and the ... guidelines for image guided radiation therapy (IGRT) and ... issue of the International Journal of Radiation ... guidelines were released as educational tools to assist ...
... reveals new way to repair damage with natural tissue ... nanofiber gel that promotes cartilage growth in joints has ... injected into the damaged joint and stimulates bone marrow ... for expensive growth factors. No current therapy can do ...
... , ... Foundation and Shands HealthCare announce today that they have ... needs assessment for a Gainesville -based children,s hospital. The assessment began ... , "We are confident that the experts at Sg2 will ...
... , NEW YORK , Feb. 4 ... announced more than $2.8 million in awards for ... PD. The development of biomarkers is of critical importance to ... scientists and clinicians to more accurately identify appropriate subjects for ...
... February 4, 2010 -- Giving smokers information about their ... to quit smoking, according to a paper published in ... "Personalized risk assessment has been the mainstay of ... mortality reduction over the last decade," said Dr. Robert ...
Cached Medicine News:Health News:Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites 2Health News:ASTRO, ACR issue IGRT, SBRT guidelines 2Health News:Nanofiber Gel May Spur Growth of New Knee Cartilage 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 2Health News:Sebastian Ferrero Foundation and Shands HealthCare Have Selected Sg2 to Conduct a Needs Assessment for a Gainesville-Based Children's Hospital 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 2Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 3Health News:Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinson's Disease Biomarker Pipeline 4Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 2Health News:Tests showing smokers their individual risk of future disease will help them quit, says paper 3
Anorectal Stylet for LATITUDE® Air-Charged Catheter...
Omnilink Adapter Cable for LATITUDE® Air-Charged Catheter...
Solid State Manometry Catheter Accessory., ,Manometric calibrators are required for calibration of solid state catheters., ,Each type of catheter requires a unique calibrator....
... The ITREL 3 is a battery ... in the U.S., ,Enterra™ Therapy is ... and vomiting associated with gastroparesis when conventional ... of symptons for diabetic or idiopathic patients., ...
Medicine Products: